they keep on referencing RP11 as a ‘co-lead’ ; reading it simply as a layman (which I am) I’m assuming ADOA has been worked up to a point where it’s ‘ready’? Maybe they’ve been working up ADOA through GLP/PK in stealth and its IND ready? (Just trying to make sense of the delays to date)
I think the team here is already fully informed, but there’s a lot for other shareholders/market to catch up on:
1) GLP status
2) PK relevance
3) Patent expansion/Pipeline beyond the co-leads: CNS, Kidney, Neurodegenerative
Ann: PK STUDY RESULTS MOVE RP11 CLOSER TO FIRST IN HUMAN TRIALS, page-104
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.005(4.76%) |
Mkt cap ! $501.6M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.0¢ | 10.5¢ | $312.1K | 2.859M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 623924 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 714192 | 14 |
View Market Depth
| Last trade - 15.25pm 23/07/2024 (20 minute delay) ? |
| PYC (ASX) Chart |